When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 53, Issue 2, 2005, Pages 115-123

  Brahimi Horn, Christiane ^a   Pouysségur, Jacques ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cancer; Hypoxia; Hypoxia inducible factor 1; Post translational modification; Prolyl hydroxylase domain protein; Proteasome; SUMO; Ubiquitin; von Hippel Lindau

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRINOTECAN; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEASOME; PROTEASOME INHIBITOR; TOPOTECAN; UBIQUITIN;

ADAPTATION; ALPHA CHAIN; CANCER CHEMOTHERAPY; CELL FUNCTION; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; ENZYME INHIBITION; GENE ACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYDROXYLATION; HYPOXIA; MAMMAL CELL; MULTIPLE MYELOMA; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR CELL; UBIQUITINATION;

ANOXIA; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; UBIQUITIN;

EID: 12344329398     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.09.003     Document Type: Review

References (59)

1. C.M. Pickart, and R.E. Cohen Proteasomes and their kin: proteases in the machine age Nat Rev Mol Cell Biol 5 2004 177 187
2. M. Muratani, and W.P. Tansey How the ubiquitin-proteasome system controls transcription Nat Rev Mol Cell Biol 4 2003 192 201
3. R.C. Aguilar, and B. Wendland Ubiquitin: not just for proteasomes anymore Curr Opin Cell Biol 15 2003 184 190
4. G.L. Semenza Targeting HIF-1 for cancer therapy Nat Rev Cancer 3 2003 721 732
5. N.M. Mazure, M.C. Brahimi-Horn, and J. Pouyssegur Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis Curr Pharm Des 9 2003 531 541
6. N. Masson, and P.J. Ratcliffe HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels J Cell Sci 116 2003 3041 3049
7. C.W. Pugh, and P.J. Ratcliffe The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis Semin Cancer Biol 13 2003 83 89
8. C.W. Liu, M.J. Corboy, G.N. DeMartino, and P.J. Thomas Endoproteolytic activity of the proteasome Science 299 2003 408 411
9. D.A. Chan, P.D. Sutphin, N.C. Denko, and A.J. Giaccia Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha J Biol Chem 277 2002 40112 40117
10. M.A. Maynard, H. Qi, and J. Chung Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex J Biol Chem 278 2003 11032 11040
11. P.C. Mahon, K. Hirota, and G.L. Semenza FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity Genes Dev 15 2001 2675 2686
12. P. Koivunen, M. Hirsila, V. Gunzler, K.I. Kivirikko, and J. Myllyharju Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases J Biol Chem 2003
13. R. Ravi, B. Mookerjee, and Z.M. Bhujwalla Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha Genes Dev 14 2000 34 44
14. D. Chen, M. Li, J. Luo, and W. Gu Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function J Biol Chem 278 2003 13595 13598
15. M.K. Bae, M.Y. Ahn, and J.W. Jeong Jab1 interacts directly with HIF-1alpha and regulates its stability J Biol Chem 277 2002 9 12
16. J.W. Jeong, M.K. Bae, and M.Y. Ahn Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation Cell 111 2002 709 720
17. M.J. Carrozza, R.T. Utley, J.L. Workman, and J. Cote The diverse functions of histone acetyltransferase complexes Trends Genet 19 2003 321 329
18. T. Kouzarides Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19 2000 1176 1179
19. Z. Li, D. Wang, X. Na, S.R. Schoen, E.M. Messing, and G. Wu Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor Biochem Biophys Res Commun 294 2002 700 709
20. Z. Li, X. Na, D. Wang, S.R. Schoen, E.M. Messing, and G. Wu Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein J Biol Chem 277 2002 4656 4662
21. H. Okuda, K. Saitoh, and S. Hirai The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C J Biol Chem 276 2001 43611 43617
22. X. Na, H.O. Duan, and E.M. Messing Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein EMBO J 22 2003 4249 4259
23. A.V. Kuznetsova, J. Meller, and P.O. Schnell von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination Proc Natl Acad Sci USA 100 2003 2706 2711
24. S.A. Shah, M.W. Potter, and T.P. McDade 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer J Cell Biochem 82 2001 110 122
25. J.B. Sunwoo, Z. Chen, and G. Dong Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clin Cancer Res 7 2001 1419 1428
26. J. Adams The proteasome: structure, function, and role in the cell Cancer Treat Rev 29 Suppl 1 2003 3 9
27. V. Jesenberger, and S. Jentsch Deadly encounter: ubiquitin meets apoptosis Nat Rev Mol Cell Biol 3 2002 112 121
28. P.M. Voorhees, E.C. Dees, B. O'Neil, and R.Z. Orlowski The proteasome as a target for cancer therapy Clin Cancer Res 9 2003 6316 6325
29. B.A. Teicher, G. Ara, R. Herbst, V.J. Palombella, and J. Adams The proteasome inhibitor PS-341 in cancer therapy Clin Cancer Res 5 1999 2638 2645
30. J.C. Cusack Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib Cancer Treat Rev 29 Suppl 1 2003 21 31
31. S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D.J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol Cancer Ther 3 2004 59 70
32. T.T. Huang, S.M. Wuerzberger-Davis, Z.H. Wu, and S. Miyamoto Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress Cell 115 2003 565 576
33. F. Melchior, M. Schergaut, and A. Pichler SUMO: ligases, isopeptidases and nuclear pores Trends Biochem Sci 28 2003 612 618
34. J.S. Seeler, and A. Dejean Nuclear and unclear functions of SUMO Nat Rev Mol Cell Biol 4 2003 690 699
35. Bracken CP, Whitelaw ML, Peet DP. The NF-kB essential modulator (NEMO/IKK-g) physically and functionally interacts with HIF-2a. Keystone Symposia Conference. Biology of hypoxia: the role of oxygen sensing in development, normal function and disease; 2004.
36. M. Tojo, K. Matsuzaki, and T. Minami The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system J Biol Chem 277 2002 46576 46585
37. D. Chauhan, G. Li, and K. Podar Targeting mitochondria to overcome conventional and Bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells Blood 2004
38. C. Brahimi-Horn, E. Berra, and J. Pouyssegur Hypoxia: the tumor's gateway to progression along the angiogenic pathway Trends Cell Biol 11 2001 S32 S36
39. S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D.J. McConkey Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts Mol Cancer Ther 2 2003 835 843
40. H.M. Sowter, M. Ferguson, and C. Pym Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade J Pathol 201 2003 573 580
41. C.C. Wykoff, C.W. Pugh, P.H. Maxwell, A.L. Harris, and P.J. Ratcliffe Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling Oncogene 19 2000 6297 6305
42. R.K. Bruick Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia Proc Natl Acad Sci USA 97 2000 9082 9087
43. H.M. Sowter, P.J. Ratcliffe, P. Watson, A.H. Greenberg, and A.L. Harris HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors Cancer Res 61 2001 6669 6673
44. P. Carmeliet, Y. Dor, and J.M. Herbert Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis Nature 394 1998 485 490
45. A. Unruh, A. Ressel, and H.G. Mohamed The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy Oncogene 22 2003 3213 3220
46. K. Brusselmans, F. Bono, and P. Maxwell Hypoxia-inducible factor-2alpha (HIF-2alpha) is involved in the apoptotic response to hypoglycemia but not to hypoxia J Biol Chem 276 2001 39192 39196
47. K. Kondo, J. Klco, E. Nakamura, M. Lechpammer, and W.G. Kaelin Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 1 2002 237 246
48. J.K. Maranchie, J.R. Vasselli, J. Riss, J.S. Bonifacino, W.M. Linehan, and R.D. Klausner The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 1 2002 247 255
49. Y. Makino, R. Cao, and K. Svensson Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression Nature 414 2001 550 554
50. A. Rapisarda, B. Uranchimeg, and D.A. Scudiero Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 2002 4316 4324
51. A. Rapisarda, B. Uranchimeg, O. Sordet, Y. Pommier, R.H. Shoemaker, and G. Melillo Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications Cancer Res 64 2004 1475 1482
52. L.F. Liu, S.D. Desai, T.K. Li, Y. Mao, M. Sun, and S.P. Sim Mechanism of action of camptothecin Ann NY Acad Sci 922 2000 1 10
53. P. Rallabhandi, K. Hashimoto, Y.Y. Mo, W.T. Beck, P.K. Moitra, and P. D'Arpa Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin J Biol Chem 277 2002 40020 40026
54. Y.Y. Mo, Y. Yu, Z. Shen, and W.T. Beck Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein J Biol Chem 277 2002 2958 2964
55. K. Horie, A. Tomida, and Y. Sugimoto SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin Oncogene 21 2002 7913 7922
56. Berta M, Mazure N, Hattab M, Pouysségur J, Brahimi-Horn MC. Hypoxia-inducible factor-1a is modified by covalent attachment to SUMO. Keystone Symposia Conference. Biology of hypoxia: the role of oxygen sensing in development, normal function and disease; 2004.
57. G. Nalepa, and J. Wade Harper Therapeutic anti-cancer targets upstream of the proteasome Cancer Treat Rev 29 Suppl 1 2003 49 57
58. P. Chene Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat Rev Cancer 3 2003 102 109
59. L.T. Vassilev, B.T. Vu, and B. Graves In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848